军事知识服务平台
Janus激酶抑制剂在儿童少见皮肤疾病治疗中的应用进展
Advances in the application of Janus kinase inhibitors for the uncommon pediatric dermatological disorders
摘要 Janus激酶(JAK)抑制剂因可靶向阻断JAK信号转导和转录激活因子信号通路而在儿童炎症介导的自身免疫性皮肤疾病中成为研究热点。本文围绕JAK抑制剂的作用机制、获批适应证展开梳理,并系统阐述其在儿童扁平苔藓、结缔组织病、化脓性汗腺炎、A20单倍剂量不足、慢性非典型性中性粒细胞性皮肤病-脂质营养不良-体温升高综合征等少见皮肤疾病中的有效性及安全性数据,为优化此类儿童皮肤病治疗方案提供新选择。
Abstract:
Janus kinase (JAK) inhibitors have emerged as a research hotspot in pediatric inflammation-mediated autoimmune skin diseases, owing to the ability to target and block the JAK-signal transducer and activator of transcription (JAK-STAT) signaling pathway. This article summarizes the mechanism of action and approved indications of JAK inhibitors, and systematically reviews the efficacy and safety data in pediatric uncommon skin diseases such as lichen planus, connective tissue diseases, hidradenitis suppurativa, haploinsufficiency of A20, and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome, aiming to provide new options for optimizing therapeutic regimens for those pediatric skin diseases.
刊 名 中华预防医学杂志 ISTICPKU
年,卷(期): 2026, 60(10)
在线出版日期: 2026年10月6日